AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics
2026-04-21 15:02:07 ET
The last time I wrote about AnaptysBio ( ANAB ) it was with a Seeking Alpha article entitled " AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement ." Regarding this article, I mentioned that the company had discontinued its development of its pathogenic T-cell depleter rosnilimab for the treatment of patients with ulcerative colitis [UC]. However, what I also mentioned is that the company had achieved positive results from the phase 2b RENOIR study using this very same drug to treat patients with moderate-to-severe rheumatoid arthritis [RA]. The last time I had placed a "Hold" rating on this stock, and it has traded higher by 52.87% since I last mentioned it....
Read the full article on Seeking Alpha
For further details see:
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics
NASDAQ: NVS
NVS Trading
-0.26% G/L:
$150.47 Last:
852,043 Volume:
$151.84 Open:
